Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients
Authors:
- 1 June 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 13 (6) , 727-732
Abstract
Background. Tumor necrosis factor alpha (TNFα) is a proinflammatory cytokine and an important mediator in the pathophysiology of inflammatory bowel disease (IBKeywords
This publication has 46 references indexed in Scilit:
- TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre studyGenes & Immunity, 2004
- Soluble tumor necrosis factor (TNF) receptor‐1 induces apoptosis via reverse TNF signaling and autocrine transforming growth factor‐β1The FASEB Journal, 2004
- Etanercept in psoriasisExpert Opinion on Pharmacotherapy, 2004
- Treatment with Soluble Tumor Necrosis Factor Receptor (sTNFR):Fc/p80 Fusion Protein Ameliorates Relapsing-remitting Experimental Autoimmune Encephalomyelitis and Decreases Chemokine ExpressionAutoimmunity, 2004
- Etanercept treatment of renal amyloidosis complicating rheumatoid arthritisInternal Medicine Journal, 2004
- Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1Rheumatology, 2004
- Up-regulation of Soluble Tumor Necrosis Factor Receptor Two in Plasma of HIV-Seropositive Individuals Who Use OpiatesAIDS Research and Human Retroviruses, 2004
- TNF-α antagonists for the treatment of Crohn’s diseaseExpert Opinion on Pharmacotherapy, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Shedding of tumor necrosis factor receptors by activated human neutrophils.Journal of Experimental Medicine, 1990